Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Cytarabine 184Cyclophosphamide 176fludarabine 146Azacitidine 121venetoclax 115fludarabine phosphate 104Rituximab 80Decitabine 74Filgrastim 58Specimen Handling 55Etoposide 55Lenalidomide 47Biopsy 45Dexamethasone 41Methotrexate 40Bortezomib 40Mitoxantrone 39Granulocyte Colony-Stimulating Factor 39Daunorubicin 39Vincristine 37Melphalan 36ibrutinib 35Tacrolimus 35Dasatinib 34Whole-Body Irradiation 32Clofarabine 32Peripheral Blood Stem Cell Transplantation 31Mycophenolic Acid 31Injections 31Idarubicin 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × AZD0466 × Other hematologic neoplasm × Clear all
NCT04214093 2023-08-02

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

AstraZeneca

Phase 1 Terminated
9 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Recurrence, Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡